Simultaneous Determination of Hydrochlorothiazide and Propranolol Hydrochloride in Powder Mixture and Matrix Tablet Using First Derivative Ultraviolet Spectrophotoscopy


Article Preview

Normal UV-spectrophotoscopy [D0] cannot determine the combined drug in the formulation due to overlapping of the absorbance of each compound hence the derivative UV-spectrophotoscopy is used to determine the combined drug simultaneously. For determination of both hydrochlorothiazide [HCT] and propranolol hydrochloride [Pro] in powder mixture and matrix tablet, the first order derivative UV-spectrophotoscopy [D1] was employed in this study. This method showed good accuracy and precision for simultaneous determination of both drugs. Recovery was 106.59% and 97.11% for Pro and HCT, respectively. Reproducibility of both drugs was found to be less than 2.5% RSD. Repeatability was less than 2.0% of both drugs. Limit of detection (LOD) was 0.10 and 0.49 μg/ml, respectively. Limit of quantification (LOQ) was 0.31 and 1.48 μg/ml, respectively. The drug dissolution was conducted either powder mix or matrix tablet prepared by molding technique. Both drugs in powder mixture showed faster release than that from the matrix tablets. As the results, the first derivative UV-spectrophotoscopy could separate the overlapped spectra of HCT and Pro either in powder mix or in matrix tablet hence it could be used to determine the mixture of these two drugs in dosage forms.



Advanced Materials Research (Volumes 581-582)

Edited by:

Jimmy (C.M.) Kao, Wen-Pei Sung and Ran Chen




C. E. Choncheewa and T. Phaechamud, "Simultaneous Determination of Hydrochlorothiazide and Propranolol Hydrochloride in Powder Mixture and Matrix Tablet Using First Derivative Ultraviolet Spectrophotoscopy", Advanced Materials Research, Vols. 581-582, pp. 150-153, 2012

Online since:

October 2012




[1] L. Sriphong, A. Chaidedgumjorn, K. Chaisuroj, Derivative spectrophotometry applied to the determination of triprolidine hydrochloride and pseudoephedrine hydrochloride in tablets and dissolution testing, W. A. S. E. T. 55 (2009) 573-77.

[2] C.B. Ojeda, F.S. Rojas. Recent developments in derivative ultraviolet/visible absorption spectrophotometry, Anal. Chim. Acta. 518 (2004) 1-24.


[3] Y. L. Yeow, S. Azali, S.Y. Ow, M. C. L. Wong, Y-K. Leong. Evaluating the third and fourth derivatives of spectral data, Talanta. 68 (2005) 156-64.


[4] M. Bartolomei, P. Bertocchi, M. C. Ramusino, N. Santucci, L. Valvo. Physico-chemical characterization of the modifications I and II of (R, S) propranolol hydrochloride: solubility and dissolution studies, J. Pharm. Biomed. Anal. 21 (1999) 299-309.


[5] P. Chetty. Development and assessment of propranolol sustained release dosage forms separately and in combination with hydrochlorothiazide [Thesis]. South Africa: Rhodes Univ (2006).

[6] P.D. Klimstra, B. Roniker, E.A. Swab. U.S. Patent 5, 880, 127. (1999).

[7] H. Mollel. Development and assessment of azithromycin paediatric suppository formulations [Thesis]. South Africa: Rhodes Univ (2006).